Patents Assigned to ACTUALEYES INC.
-
Patent number: 11624053Abstract: The present invention provides a method of culturing corneal endothelial cells. More specifically, the present invention provides a composition for culturing or growing corneal endothelial cells, comprising at least one agent consisting of laminins and fragments thereof which express in corneal endothelial cells. Specifically, the present invention can comprise laminin 511 (alpha5 beta1 gamma1) and laminin 512 (alpha5 beta2 gamma 1). The present invention further provides a culture container for corneal endothelial cells, which is coated with the composition of the present invention. Furthermore, the present invention provides a method for culturing corneal endothelial cells comprising the step of using the composition or the container of the present invention to culture the corneal endothelial cells.Type: GrantFiled: November 26, 2014Date of Patent: April 11, 2023Assignees: KYOTO PREFECTURAL PUBLIC UNIVERSITY CORPORATION, ActualEyes Inc., CorneaGen, Inc.Inventors: Noriko Koizumi, Naoki Okumura, Shigeru Kinoshita, Friedrich E. Kruse, Ursula Schloetzer-Schrehardt
-
Publication number: 20230057984Abstract: The present invention provides a method for the normalized culturing of corneal endothelial cells. More specifically, the present invention provides a culture-normalizing-agent of a corneal endothelial cell, comprising a fibrosis inhibitor. In detail, the present invention provides a culture-normalizing agent comprising a transforming growth factor (TGF) ? signal inhibitor. The present invention also provides a culture medium for culturing a corneal endothelial cell normally, which comprises the culture-normalizing agent according to the present invention and corneal endothelium culture components. The present invention also provides a method for culturing a corneal endothelial cell normally, comprising the step of culturing a corneal endothelial cell using the culture-normalizing agent according to the present invention or the culture medium according to the present invention.Type: ApplicationFiled: September 28, 2022Publication date: February 23, 2023Applicants: KYOTO PREFECTURAL PUBLIC UNIVERSITY CORPORATION, ActualEyes Inc., CorneaGen, Inc.Inventors: Shigeru KINOSHITA, Noriko KOIZUMI, Naoki OKUMURA
-
Publication number: 20210140965Abstract: The purpose of the present invention is to provide a method of purification and preparation of cultured corneal endothelial cells, and in particular, to provide cell surface markers for use in corneal endothelial cells not including transformed cells. Provided are cell markers for distinguishing normal cells and transformed cells, in particular normal and transformed corneal endothelium cells. These cell markers relate to specific cell surface markers, for example, to a normal corneal endothelial surface marker such as CD166, and a transformed cell surface marker such as CD73. By using the transformed cell surface marker such as CD73 to remove transformed cells by sorting, it becomes possible to improve purity of a normal cultured corneal endothelium. By using normal corneal endothelial surface marker such as CD166, or by combined use with the transformed cell surface marker, it becomes possible to provide a means for verifying the purity of a prepared corneal endothelium.Type: ApplicationFiled: December 23, 2020Publication date: May 13, 2021Applicants: KYOTO PREFECTURAL PUBLIC UNIVERSITY CORPORATION, ACTUALEYES INC., CORNEAGEN, INC.Inventors: Noriko Koizumi, Naoki Okumura, Hiroatsu HIRANO, Shigeru Kinoshita, Morio UENO
-
Patent number: 10908161Abstract: The purpose of the present invention is to provide a method of purification and preparation of cultured corneal endothelial cells, and in particular, to provide cell surface markers for use in corneal endothelial cells not including transformed cells. Provided are cell markers for distinguishing normal cells and transformed cells, in particular normal and transformed corneal endothelium cells. These cell markers relate to specific cell surface markers, for example, to a normal corneal endothelial surface marker such as CD166, and a transformed cell surface marker such as CD73. By using the transformed cell surface marker such as CD73 to remove transformed cells by sorting, it becomes possible to improve purity of a normal cultured corneal endothelium. By using normal corneal endothelial surface marker such as CD166, or by combined use with the transformed cell surface marker, it becomes possible to provide a means for verifying the purity of a prepared corneal endothelium.Type: GrantFiled: July 28, 2014Date of Patent: February 2, 2021Assignees: KYOTO PREFECTURAL PUBLIC UNIVERSITY CORPORATION, ACTUALEYES INC., CORNEAGEN. INC.Inventors: Noriko Koizumi, Naoki Okumura, Hiroatsu Hirano, Shigeru Kinoshita, Morio Ueno